815
Editorial
EJCP is renewing itself—and will soon celebrate its 40th anniversary!
And we welcome the new editor Professor Ulrich Klotz!
Rune Dahlqvist and Sandra Thake
817-819
Editorial
The bridging function of clinical pharmacology
Ulrich Klotz
821-827
Pharmacokinetics and Disposition
An in vitro approach to potential methadone metabolic-inhibition interactions
Stephanie Bomsien and Gisela Skopp
829-836
Pharmacokinetics and Disposition
Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation
Marjo J. Karjalainen, Pertti J. Neuvonen and Janne T. Backman
837-842
Pharmacokinetics and Disposition
Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery
O. Dale, J. Thoner, T. Nilsen, T. Tveita and P. C. Borchgrevink, et al.
843-849
Pharmacoepidemiology and Prescription
Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005
Joanna Watson, Lesley Wise and Jane Green
851-859
Pharmacoepidemiology and Prescription
Potential drug interactions during a three-decade study period: a cross-sectional study of a prescription register
Emelie Åstrand, Bengt Åstrand, Karolina Antonov and Göran Petersson
861-865
Pharmacoepidemiology and Prescription
Early discontinuation: more frequent among general practitioners with high levels of prescribing
Dorte Gilså Hansen, Anthony Gichangi, Werner Vach, Lina Hoel Felde and John Larsen
867-873
Pharmacoepidemiology and Prescription
Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation
Antonio Veronese, Massimo Garatti, Andrea Cipriani and Corrado Barbui
875-878
Short Communication
New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature
Andrea Cassinotti, Alessandro Massari, Elisa Ferrara, Salvatore Greco and Matteo Bosani, et al.
879-889
Point of View
New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval
Vittorio Bertele’, Alessandro Assisi, Valeria Di Muzio, Danila Renzo and Silvio Garattini
891-892
Letter to the Editors
Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes
Yasser Khazaal and Daniele Fabio Zullino
893
Letter to the Editors
About the appetite-related effects of topiramate
Angelo Tremblay and Jean-Philippe Chaput
895-896
Letter to the Editors
Interaction of clozapine and ciprofloxacin: a case report
Rajvinder S. Sambhi, Ramneesh Puri and Gaynor Jones